{"database": "lobbying", "table": "lobbying_activities", "rows": [[1629370, "57c2c74e-392d-4013-8b23-f68a44c5b05c", "Q4", "PRIME THERAPEUTICS", 400339576, "PRIME THERAPEUTICS", 2014, "fourth_quarter", "PHA", "Prescription Drug Abuse. Support of the Alliance to Prevent the Abuse of Medicines legislative priorities including minimum requirements for state databases, pharmacy lock-in programs, and abuse deterrent technology. \n\nBiosimilars - concerns regarding naming (shared names with reference product vs. original names); specialty drug cost trends\n\nHR 4577 Ensuring Seniors Access to Local Pharmacies Act - opposed\nHR 460 Patients Access to Treatment Act - opposed\nHR 4437 Medication Therapy Empowerment Act - oppose expanding to one condition", "Federal Trade Commission (FTC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)", null, 250000, 0, 0, "2015-01-19T13:02:02.017000-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1629370"], "units": {}, "query_ms": 40.99293297622353, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}